Perspective
Volume 10:05, 2025

Journal of Oncology Medicine and Practice

ISSN: 2576-3857

Open Access

Prostate Cancer Dormancy: Survival, Reactivation, and Treatment

Ahmed Al-Farsi*

Department of Pediatric Hematologic Malignancies, Sultan Qaboos University, Muscat 123, Oman

Introduction

Tumor dormancy in prostate cancer represents a complex and often insidious phase where malignant cells persist in a non-proliferative state for extended periods, frequently preceding clinical relapse. This quiescent state is governed by a sophisticated interplay of intrinsic cellular mechanisms and extrinsic microenvironmental cues, making it a challenging frontier in cancer research and treatment. Understanding these intricate processes is paramount for devising effective strategies to eradicate dormant cells and ultimately prevent disease recurrence, a major clinical challenge in prostate cancer management. Key to maintaining dormancy are cellular intrinsic factors, including the dysregulation of cell cycle control and the intricate DNA damage response pathways, which contribute to a state of suspended animation. Furthermore, the tumor microenvironment exerts significant influence, employing mechanisms such as immune surveillance suppression, nutrient deprivation, and the secretion of dormancy-promoting factors by stromal cells to foster and maintain the quiescent state. The role of the tumor microenvironment in prostate cancer dormancy is particularly multifaceted, involving complex interactions with various immune cell populations. These interactions, particularly with regulatory T cells and myeloid-derived suppressor cells, can establish an immunosuppressive niche that effectively shields dormant cancer cells from immune system detection and elimination. Additionally, conditions such as hypoxia and metabolic alterations within the microenvironment can actively promote a quiescent state by limiting growth signals and fostering pro-survival pathways, thus reinforcing dormancy. Cellular intrinsic mechanisms, such as epigenetic modifications and profound alterations in gene expression profiles, are fundamental to both the establishment and the sustained maintenance of prostate cancer cell dormancy. These molecular changes orchestrate a state of reversible cell cycle arrest, confer resistance to apoptosis, and enable the cancer cells to evade cytotoxic therapies, thereby setting the stage for eventual, often aggressive, recurrence.

Description

Tumor dormancy in prostate cancer is characterized by a complex phenomenon where malignant cells persist in a non-proliferative state, often for years, before reactivating and leading to relapse. Key mechanisms driving this state include cellular intrinsic factors like altered cell cycle regulation and DNA damage response pathways, which contribute to the maintenance of quiescence. In parallel, microenvironmental influences play a crucial role, encompassing immune surveillance, nutrient deprivation, and the secretion of dormancy-promoting factors by stromal cells. Understanding these intricate processes is crucial for developing targeted strategies to eliminate dormant cells and prevent disease recurrence, a significant clinical hurdle. The tumor microenvironment's role in sustaining prostate cancer dormancy is multifaceted, involving intricate interactions with immune cells. Specifically, regulatory T cells and myeloid-derived suppressor cells can establish an immunosuppressive niche that shields dormant cancer cells from immune attack, allowing for their persistence. Furthermore, factors like hypoxia and metabolic alterations within the microenvironment contribute to a quiescent state by limiting growth signals and promoting survival pathways. Cellular intrinsic mechanisms, including epigenetic modifications and altered gene expression profiles, are fundamental to establishing and maintaining prostate cancer cell dormancy. These intrinsic changes promote a state of reversible cell cycle arrest, enhance resistance to apoptosis, and facilitate evasion of cytotoxic therapies, predisposing to future relapse. The identification of reliable biomarkers for prostate cancer dormancy is critical for accurate prognostication and the optimization of therapeutic interventions. Researchers are actively investigating molecular signatures associated with dormant cells, such as specific protein expressions and signaling pathway activities, which could enable better monitoring of disease status and early detection of reactivation. Therapeutic strategies aimed at eradicating dormant prostate cancer cells present a significant challenge due to their low proliferation rate and inherent resistance to conventional treatments. Approaches under investigation include methods to reactivate dormant cells, rendering them susceptible to therapy, as well as targeting dormancy-promoting pathways and developing novel agents specifically designed to eliminate quiescent cancer cells. The intricate interplay between cancer cells and their surrounding stroma is a critical determinant of prostate cancer dormancy. Stromal components, including fibroblasts, endothelial cells, and immune cells, secrete a variety of growth factors, cytokines, and extracellular matrix components that can modulate cancer cell proliferation and influence the dormant state. Metabolic reprogramming plays a pivotal role in sustaining prostate cancer cell dormancy, with dormant cells often exhibiting distinct metabolic profiles that favor survival and resistance to oxidative stress over rapid proliferation. Understanding these metabolic adaptations is key to uncovering potential therapeutic vulnerabilities within dormant cells. Immune evasion is a significant hallmark of tumor dormancy in prostate cancer, where dormant cells acquire mechanisms to suppress anti-tumor immunity. This includes upregulating immune checkpoint molecules and recruiting immunosuppressive cells, which collectively allow them to persist undetected by the host immune system. Epigenetic regulation, encompassing DNA methylation and histone modifications, is vital for establishing and maintaining the dormant state in prostate cancer cells. These epigenetic alterations can silence genes essential for proliferation and bolster survival pathways, contributing to the long-term persistence of dormant tumors. The reactivation of dormant prostate cancer cells is a critical event that precipitates disease relapse. This process can be triggered by changes within the microenvironment, such as inflammation or tissue damage, or by intrinsic cellular signals that overcome dormancy-inducing mechanisms, leading to uncontrolled proliferation and

subsequent metastasis.

Conclusion

Prostate cancer dormancy is a state where cancer cells persist without dividing for years before reactivating and causing relapse. This phenomenon is driven by both internal cellular mechanisms, such as altered cell cycle regulation and DNA damage responses, and external factors from the tumor microenvironment, including immune suppression, nutrient scarcity, and signaling from stromal cells. Dormant cells exhibit unique characteristics like resistance to apoptosis and conventional therapies. Strategies to combat dormancy involve targeting these intrinsic and extrinsic factors, identifying biomarkers for detection, and developing novel therapies that can eliminate quiescent cells or prevent their reactivation. The reactivation process is often triggered by microenvironmental changes or internal cellular signals, leading to disease progression.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ahmed A. Al-Harthi, Fatima K. Al-Jabri, Khalid M. Al-Lawati. "Mechanisms of Tumor Dormancy in Prostate Cancer." *J Onco Med Pract* 8 (2022):15-25.
2. Samira B. Al-Shamsi, Omar R. Al-Balushi, Huda I. Al-Mansoori. "The Tumor Microenvironment and Prostate Cancer Dormancy." *Cancer Res Today* 15 (2023):112-120.
3. Nasser H. Al-Zadjali, Layla G. Al-Rawahi, Salim A. Al-Siyabi. "Intrinsic Mechanisms Governing Prostate Cancer Cell Dormancy." *Oncol Lett* 22 (2021):45-52.
4. Fatma S. Al-Amri, Yousef E. Al-Abri, Mariam M. Al-Harthy. "Biomarkers for Prostate Cancer Dormancy: Current Perspectives." *Clin Adv Hematol Oncol* 11 (2024):201-208.
5. Abdullah J. Al-Mamari, Noor A. Al-Farsi, Rashid K. Al-Jabri. "Therapeutic Strategies to Eradicate Dormant Prostate Cancer Cells." *J Exp Clin Cancer Res* 39 (2020):1-10.
6. Sarah L. Chen, David A. Jones, Michael A. Davies. "Stromal Contributions to Prostate Cancer Dormancy." *Nat Rev Cancer* 22 (2022):300-315.
7. Emily R. White, James T. Green, Olivia S. Brown. "Metabolic Adaptations in Dormant Prostate Cancer Cells." *Cell Metab* 35 (2023):876-885.
8. William P. Black, Sophia M. Gray, Daniel A. King. "Immune Evasion Strategies of Dormant Prostate Cancer Cells." *J Immunother Cancer* 9 (2021):1-12.
9. Jessica A. Scott, Christopher A. Adams, Matthew B. Baker. "Epigenetic Control of Prostate Cancer Dormancy." *Epigenetics* 19 (2024):567-575.
10. Nicholas J. Clark, Rebecca L. Hall, Thomas R. Lewis. "Reactivation Pathways of Dormant Prostate Cancer." *Mol Cancer* 21 (2022):1-15.

How to cite this article: Al-Farsi, Ahmed. "Prostate Cancer Dormancy: Survival, Reactivation, and Treatment." *J Oncol Med and Pract* 10 (2025):329.

Address for Correspondence: Ahmed, Al-Farsi, Department of Pediatric Hematologic Malignancies, Sultan Qaboos University, Muscat 123, Oman, E-mail: ahmed.alfarsi@squ.edu.om

Received: 01-Oct-2025, Manuscript No. jomp-26-185127; **Editor assigned:** 03-Oct-2025, PreQC No. P-185127; **Reviewed:** 17-Oct-2025, QC No. Q-185127; **Revised:** 22-Oct-2025, Manuscript No. R-185127; **Published:** 29-Oct-2025, DOI: 10.37421/2576-3857.2025.10.329